I am a
Home I AM A Search Login

Papers of the Week

2022 Jul 15

Future Oncol

Patient preferences for treatment in relapsed/refractory diffuse large B-cell lymphoma: a discrete choice experiment.


Birch K, Snider JT, Chiu K, Baumgardner J, Wade SW, Shah G
Future Oncol. 2022 Jul 15.
PMID: 35837970.


We quantified patient preferences for second-line diffuse large B-cell lymphoma therapies, including attributes of chimeric antigen receptor (CAR) T-cell therapy. Using a discrete choice experiment, we surveyed 224 diffuse large B-cell lymphoma patients from the USA and Europe. Patients chose between two treatment options defined by six attributes with predefined levels for overall survival, adverse events (severe cytokine-release syndrome, severe neurological toxicities, severe infection) and time to return to pre-treatment functioning. Increasing the probability of 1-year survival was most important to patients, followed by avoiding risks of cytokine-release syndrome and neurological toxicities. Respondents required a 13-14 percentage point increased 1-year survival probability to accept risks of treatment-associated adverse events. Patients prioritize survival and will accept certain adverse event risks to gain survival improvements.